LUNG CANCER

October 8, 2021

Fam-Trastuzumab Deruxtecan-Nxki Promising Against HER2-Mutated NSCLC

October 8, 2021

Disparities in Lung Cancer-Screening Eligibility Persist

October 8, 2021

FDA Approves First Oral Therapy for EGFR Exon20 Insertion+ NSCLC

September 22, 2021

FDA Grants Priority Review to Atezolizumab for Early Non-Small Cell Lung Cancer

September 22, 2021

Lung Cancer Screening Rates Mostly Unchanged During Pandemic

September 22, 2021

Cemiplimab Considerably Improved Overall Survival in Patients With Advanced NSCLC

August 12, 2021

No Clinical Benefit From Ipilimumab Plus Nivolumab in Squamous NSCLC

August 12, 2021

FDA Approves First Targeted Treatment for NSCLC Patients With EGFR Mutations

August 12, 2021

CHEST Releases Expert Guideline for Lung Cancer Screening

July 26, 2021

Promising Study Results for Pralsetinib in Patients With RET Fusion–Positive NSCLC

July 26, 2021

First Targeted Therapy Approved for Adults With KRAS G12 C–Mutated NSCLC

July 26, 2021

Durvalumab and Stereotactic Body Radiotherapy Combination

December 16, 2020

New Dosing Option Approved for Durvalumab in NSCLC

October 2021

October 2021

In This Issue Digital Magazine Archives Subscription

Take Quiz

Ovarian Cancer

Copyright © 2000 - 2021 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.